文献速递乳腺外科

微创乳腺手术与传统乳腺手术的长期肿瘤学预后比较

Association of Long-term Oncologic Prognosis With Minimal Access Breast Surgery vs Conventional Breast Surgery.
PubMed 文献 · JAMA Surg · 2022-12-14

该单中心回顾性队列研究纳入2412例0-III期女性乳腺癌患者,比较微创乳腺手术(MABS)与传统乳腺手术(CBS)的长期预后。中位随访84个月,两组10年局部无复发生存率、区域无复发生存率、远处无转移生存率及5年、10年、15年无病生存率和总生存率均无显著差异。结论认为MABS在早期乳腺癌中可能是安全可行的替代选择。

要点

  • MABS与CBS的10年局部无复发生存率、区域无复发生存率、远处无转移生存率均无显著差异。
  • 两组5年、10年、15年无病生存率和总生存率差异无统计学意义。
  • MABS可作为早期乳腺癌患者安全可行的替代选择。

核心结论

  • 在早期乳腺癌患者中,MABS的长期肿瘤学结局与CBS无显著差异,MABS可能是安全可行的替代选择。

研究设计与样本

  • 单中心回顾性队列研究,评估9184例个体,最终纳入2412例0-III期成年女性乳腺癌患者,行单侧乳腺手术,无远处转移或严重基础疾病史,采用倾向性评分匹配减少选择偏倚。

主要发现

  • MABS组603例(内镜、内镜辅助和机器人辅助分别为289、302和12例),CBS组1809例,中位随访84个月(MABS组93个月,CBS组80个月)。
  • 事后亚组分析显示无病生存率组间差异均无统计学意义。

临床怎么用

  • 对于早期乳腺癌患者,MABS可作为CBS的可行替代方案,但需结合患者具体情况和术者经验选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Minimal access breast surgery (MABS) has been used in breast cancer management. However, long-term prognostic data associated with MABS vs conventional breast surgery (CBS) are lacking. OBJECTIVE: To investigate long-term therapeutic outcomes associated with MABS vs CBS for breast cancer management. DESIGN, SETTING, AND PARTICIPANTS: In this single-center retrospective cohort study, 9184 individuals were assessed for inclusion. After exclusions, 2412 adult female individuals were included who were diagnosed with stage 0 to III breast cancer, underwent unilateral breast surgery between January 2004 and December 2017, and had no distant metastasis or history of severe underlying disease. Propensity score matching was performed to minimize selection bias. Data were analyzed from January 1, 2004, to December 31, 2019. EXPOSURES: MABS or CBS. MAIN OUTCOMES AND MEASURES: Data on demographic and tumor characteristics and long-term outcomes were collected and analyzed. RESULTS: This study included 2412 patients (100% female; median [IQR] age, 44 [40-49] years). Of these, 603 patients underwent MABS (endoscopic, endoscopy-assisted, or robot-assisted procedures in 289, 302, and 12 patients, respectively) and 1809 patients underwent CBS. The median follow-up time was 84 months (93 in the MABS group and 80 months in the CBS group). Intergroup differences were not significant for the following parameters: 10-year local recurrence-free survival (93.3% vs 96.3%; hazard ratio [HR], 1.39; 95% CI, 0.86-2.27; P = .18), regional recurrence-free survival (95.5% vs 96.7%; HR, 1.38; 95% CI, 0.81-2.36; P = .23), and distant metastasis-free survival (81.0% vs 82.0%; HR, 0.95; 95% CI, 0.74-1.23; P = .72). The 5-, 10-, and 15-year disease-free survival rates in the MABS group were 85.9%, 72.6%, and 69.1%, respectively. The corresponding rates in the CBS group were 85.0%, 76.6%, and 70.7%. The intergroup differences were not significant (HR, 1.07; 95% CI, 0.86-1.31; P = .55). The 5-, 10-, and 15-year overall survival rates in the MABS group were 92.0%, 83.7%, and 83.0%, respectively. The corresponding rates in the CBS group were 93.6%, 88.7%, and 81.0%. The intergroup differences were not significant (HR, 1.29; 95% CI, 0.97-1.72; P = .09). Post hoc subgroup analysis showed no significant intergroup differences in disease-free survival. CONCLUSIONS AND RELEVANCE: In this cohort study, long-term outcomes following MABS were not significantly different from those following CBS in patients with early-stage breast cancer. MABS may be a safe and feasible alternative in this patient population.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Wan A, Liang Y, Chen L, et al. Association of Long-term Oncologic Prognosis With Minimal Access Breast Surgery vs Conventional Breast Surgery. JAMA Surg. 2022. PMID: 36197680. doi:10.1001/jamasurg.2022.4711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。